CVPath Yearly Summary: 2023
January 8th, 2024Dear Friends and Colleagues of CVPath, On behalf of everyone at CVPath Institute, it is my pleasure to wish you,…
Read moreDr. Virmani at CVIT 2023
August 14th, 2023Dr. Renu Virmani recently attended the 31st Annual Meeting of the Japanese Society of Cardiovascular Intervention and Therapeutics (CVIT2023) held…
Read moreEnhanced Thromboresistance and Endothelialization of a Novel Fluoropolymer-Coated Left Atrial Appendage Closure Device
July 3rd, 2023This original Research Paper was recently published in the online JACC Journal and authored by: Walid I. Saliba, Kenji Kawai,…
Read moreHistologic Assessment of Thromboemboli Due to Plaque Rupture, Plaque Erosion, or COVID-19 Microthrombi
July 3rd, 2023Recent article posted in the JACC publication of research completed at CVPath by Takao Konishi, Kenji Kawai, Rika Kawakami, Saikat…
Read moreCD163+ Macrophages restrain Vascular Calcification Research Published
March 9th, 2023A CVPath study was recently published in the JCI Insight online magazine. This research spanned several years with post-doc fellows…
Read more2022 Year in Review
January 10th, 2023Dear CVPath Friends and Colleagues, On behalf of everyone here at the CVPath Institute, it is my pleasure to wish…
Read moreBest Female Scientists in the World 2022 Ranking
October 25th, 2022CVPath would like to extend its congratulations to Dr. Virmani, who is listed as one of the best female scientists…
Read moreCVPath Pathology Study Presented at TCT
September 27th, 2022At the recent TCT 2022 conference held in Boston, MA, Dr. Aloke Finn, Primary Investigator and Dr. Yu Sato, lead…
Read moreYu Sato Recipient of Inaugural Renu Virmani Research Scholar Award
July 13th, 2022Congratulations to Dr. Yu Sato who was presented the first Renu Virmani Research Scholar Award on Friday, July 8 in…
Read moreClinical Spectrum of PASC: Focus on Cardio-pulmonary Function
July 13th, 2022Dr. Aloke Finn was a panelist on June 28 for a seminar in the R3 series titled, “Clinical Spectrum of…
Read more